Major Depression Clinical Trials

Find Major Depression Clinical Trials Near You

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder

Status: Active_not_recruiting
Location: See all (50) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 74
Healthy Volunteers: f
View:

• Adults ≥18 and ≤74 years of age and experienced their first major depressive episode (MDE) prior to 50 years of age

• Body Mass Index (BMI) ≤40 kg/m2

• Meets the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) criteria for current major depressive disorder and is currently in an MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI)

• Participant's current MDE has a duration of ≥6 weeks and ≤24 months.

Locations
United States
Alabama
Harmonex Neuroscience Research
Dothan
University of Alabama at Birmingham, Huntsville Regional Medical Campus
Huntsville
Arkansas
Pillar Clinical Research
Bentonville
SanRo Clinical Research Group
Bryant
California
Clinical Innovations Inc
Bellflower
Center for Neurohealth
La Jolla
Artemis Institute for Clinical Research
San Diego
California Neuroscience Research
Sherman Oaks
Pacific Clinical Research Management Group
Upland
Connecticut
Institute of Living
Hartford
Florida
Gulfcoast Clinical Research Center
Fort Myers
Sarkis Clinical Trials
Gainesville
Equipath Health and Research Tampa Bay, Llc
Riverview
Georgia
Delricht Research
Atlanta
Emory University Brain Health Center
Atlanta
Illinois
Advanced Quality Medical Research
Orland Park
Louisiana
Smart Trials, LLC
Jefferson
Massachusetts
Adams Clinical Boston
Boston
Activmed Practices & Research, Llc - Methuen
Methuen
Adams Clinical Watertown
Watertown
Vitalix Clinical, Inc
Worcester
Maryland
Pharmasite Research Inc.
Baltimore
Missouri
Psychiatric Care and Research Center
O'fallon
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles
North Carolina
Magnolia Clinical Research, Llc
Cary
New Jersey
Lumina Clinical Research Center
Cherry Hill
Princeton Medical Institute
Princeton
Bio Behavioral Health
Toms River
New York
Bioscience Research, LLC
Mount Kisco
Fieve Clinical Research, Inc.
New York
IMA Clinical Research
New York
Ohio
Insight Clinical Trials
Independence
Oklahoma
Sooner Clinical Research
Oklahoma City
Texas
Austin Clinical Trial Partners
Austin
Utah
Boeson Research
Provo
Other Locations
Finland
Suomen Terveystalo Oy
Helsinki
Oulu Mentalcare Oy
Oulu
Germany
Charite - Universitatsmedizin Berline
Berlin
Boehm-Peters PartGmbB - Praxis fur Psychiatrie, Psychotherapie, Neurologie
Rosenheim
Poland
In Vivo Sp. z.o.o.
Bydgoszcz
Clinical Medical Research Sp. z o.o.
Katowice
Praktyka Lekarska Malgorzata Wojtanowska-Bogacka
Poznan
Specjalistyczna Praktyka Lekarska, Filip Rybakowski
Poznan
Romania
Centru De Evaluare Si Tratament A Toxicodependentenlor Pentru Tineri Sf. Stelian
Bucharest
Clinica Nutrimed Cercetare Sr
Bucharest
Institutul Privat De Cercetari Melchisedec (ICPM) Pentru Boli Autoimune Ereditare si Rare - ICPM
Craiova
Slovakia
Dana Ignjatovićová, spol. s r.o
Banská Bystrica
Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu Liptovsky Mikulas
Liptovský Mikuláš
Spain
Hospital Universitari Vall D'Hebron
Barcelona
Hospital Universitario Son Espases
Palma De Mallorca
Time Frame
Start Date: 2025-07-08
Completion Date: 2027-07
Participants
Target number of participants: 450
Treatments
Experimental: Azetukalner
Azetukalner 20 mg
Placebo_comparator: Placebo
Placebo
Related Therapeutic Areas
Sponsors
Leads: Xenon Pharmaceuticals Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials